Table 1.

ECOFF and CBP of different antifungal agents and fungal species.^a

Species	Method	ECOFF (μg/ml)			CBP (μg/ml)
		Fluconazole	Anidulafungin	Micafungin	Fluconazole		Anidulafungin		Micafungin
					Sb	Rb	S	R	S	R
C. albicans	CLSI	0.5	≤0.12	≤0.03	2	4	0.25	0.5	0.25	0.5
	EUCAST	1	0.03	0.015	2	4	0.03	0.03	0.016	0.016
C. glabrata	CLSI	32	≤0.25	≤0.03	0.002	32	0.12	0.25	0.06	0.12
	EUCAST	32	0.06	0.03	0.002	32	0.06	0.06	0.03	0.03
C. parapsilosis	CLSI	2	≤4	≤4	2	4	2	4	2	4
	EUCAST	2	4	2	2	4	0.002	4	0.002	2
C. tropicalis	CLSI	2	≤0.12	≤0.12	2	4	0.25	0.5	0.25	0.5
	EUCAST	2	0.06	0.06	2	4	0.06	0.06	NAc	NA
C. krusei	CLSI	64	≤0.12	≤0.12	–d	–	0.25	0.5	0.25	0.5
	EUCAST	128	0.06	0.25	–	–	0.06	0.06	NA	NA

^aData obtained from published studies (11, 13, 15–18).

^bCategorical discrimination between resistant (R) and susceptible (S).

^cNA, not available. EUCAST indicates that there is not yet available evidence that the species in question is a good target for therapy with the drug.

^d“–” indicates that susceptibility testing is not recommended as the species is a poor target for therapy with the drug.

ECOFF, epidemiological cut-off; CBP, clinical breakpoint.